A quantitative comparison between the essential medicines for rheumatic diseases in children and young people in Africa and the WHO model list.
Africa
Children
Essential medicines
Joint diseases
Juvenile rheumatic diseases
WHO
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
received:
19
01
2024
accepted:
30
05
2024
medline:
5
7
2024
pubmed:
5
7
2024
entrez:
4
7
2024
Statut:
epublish
Résumé
The World Health Organisation Essential Medicines List (WHO EML) guides National Essential Medicines Lists and Standard Treatment Guidelines for clearly identified disease priorities especially in low- and middle-income countries. This study compares the degree to which the basket of medicines recommended for rheumatic diseases in children and young people in National Essential Medicines Lists of countries in the WHO Africa region, corresponds to the 2021 WHO EML and WHO EML for children, as a proxy of availability. An online search of the WHO medicines and health technology portal, the Health Ministry websites of the 54 African countries, PUBMED and Google Scholar, with search terms for 'National Essential Medicines List', AND/OR 'standard treatment guidelines' AND/OR 'Lista Nacional de Medicamentos Essenciais' AND/ OR 'Liste Nationale de Medicaments Essentiels' AND Africa AND/OR < Name of African country > was conducted. The number of medicines on the national lists were compared according to a predefined template of medicines; and the percentage similarity calculated. Descriptive statistics were derived using STATA. Forty-seven countries in the WHO Africa region have developed a National Essential Medicines List. Eleven countries do not have any medicines listed for rheumatic diseases. The majority of countries had less than or equal to 50% similarity with the WHO EML for rheumatic disease in children and young people, median 3 medicines (IQR 1- 4). The most common medicines on the national lists from Africa were methotrexate, sulfasalazine and azathioprine, with etanercept available in 6 countries. Seven countries had only one medicine, acetylsalicylic acid listed in the section 'Juvenile Joint diseases'. A multiple linear regression model for the predictors of the number of medicines on the national lists established that 20% of the variability was predicted by health expenditure per capita, socio-demographic index and the availability of rheumatology services (adult and/or paediatric) p = 0.006, with socio-demographic index (p = 0.035, 95% CI 0.64-16.16) and the availability of rheumatology services (p = 0.033, 95% CI 0.13 - 2.90) significant. Four countries (8.5%) in Africa have updated their National Essential Medicines Lists to reflect adequate care for children and young people with rheumatic diseases. Moving forward, efforts should focus on aligning available medicines with the WHO EML, and strengthening healthcare policy for rheumatology and pharmaceutical services, for affordable access to care and medicines.
Sections du résumé
BACKGROUND
BACKGROUND
The World Health Organisation Essential Medicines List (WHO EML) guides National Essential Medicines Lists and Standard Treatment Guidelines for clearly identified disease priorities especially in low- and middle-income countries. This study compares the degree to which the basket of medicines recommended for rheumatic diseases in children and young people in National Essential Medicines Lists of countries in the WHO Africa region, corresponds to the 2021 WHO EML and WHO EML for children, as a proxy of availability.
METHODS
METHODS
An online search of the WHO medicines and health technology portal, the Health Ministry websites of the 54 African countries, PUBMED and Google Scholar, with search terms for 'National Essential Medicines List', AND/OR 'standard treatment guidelines' AND/OR 'Lista Nacional de Medicamentos Essenciais' AND/ OR 'Liste Nationale de Medicaments Essentiels' AND Africa AND/OR < Name of African country > was conducted. The number of medicines on the national lists were compared according to a predefined template of medicines; and the percentage similarity calculated. Descriptive statistics were derived using STATA.
RESULTS
RESULTS
Forty-seven countries in the WHO Africa region have developed a National Essential Medicines List. Eleven countries do not have any medicines listed for rheumatic diseases. The majority of countries had less than or equal to 50% similarity with the WHO EML for rheumatic disease in children and young people, median 3 medicines (IQR 1- 4). The most common medicines on the national lists from Africa were methotrexate, sulfasalazine and azathioprine, with etanercept available in 6 countries. Seven countries had only one medicine, acetylsalicylic acid listed in the section 'Juvenile Joint diseases'. A multiple linear regression model for the predictors of the number of medicines on the national lists established that 20% of the variability was predicted by health expenditure per capita, socio-demographic index and the availability of rheumatology services (adult and/or paediatric) p = 0.006, with socio-demographic index (p = 0.035, 95% CI 0.64-16.16) and the availability of rheumatology services (p = 0.033, 95% CI 0.13 - 2.90) significant.
CONCLUSION
CONCLUSIONS
Four countries (8.5%) in Africa have updated their National Essential Medicines Lists to reflect adequate care for children and young people with rheumatic diseases. Moving forward, efforts should focus on aligning available medicines with the WHO EML, and strengthening healthcare policy for rheumatology and pharmaceutical services, for affordable access to care and medicines.
Identifiants
pubmed: 38965620
doi: 10.1186/s12969-024-00997-x
pii: 10.1186/s12969-024-00997-x
doi:
Substances chimiques
Drugs, Essential
0
Antirheumatic Agents
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Informations de copyright
© 2024. The Author(s).
Références
Global Burden of Disease. Available from: https://www.thelancet.com/gbd . Accessed 19 Dec 2023.
Malviya A, Rushton SP, Foster HE, Ferris CM, Hanson H, Muthumayandi K, et al. The relationships between adult juvenile idiopathic arthritis and employment. Arthritis Rheum. 2012;64(9):3016–24. https://doi.org/10.1002/art.34499 .
doi: 10.1002/art.34499
pubmed: 22653553
Schlichtiger J, Haas JP, Barth S, Bisdorff B, Hager L, Michels H, et al. Education and employment in patients with juvenile idiopathic arthritis - a standardized comparison to the German general population. Pediatr Rheumatol Online J. 2017;15(1):45. https://doi.org/10.1186/s12969-017-0172-2 .
doi: 10.1186/s12969-017-0172-2
pubmed: 28532479
pmcid: 5440947
Minden K, Niewerth M, Listing J, Biedermann T, Schöntube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(7):836–42. https://doi.org/10.1136/ard.2003.008516 .
doi: 10.1136/ard.2003.008516
pubmed: 15194580
pmcid: 1755057
Consolaro A, Giancane G, Alongi A, van Dijkhuizen EHP, Aggarwal A, Al-Mayouf SM, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health. 2019;3(4):255–63. https://doi.org/10.1016/S2352-4642(19)30027-6 .
doi: 10.1016/S2352-4642(19)30027-6
pubmed: 30819662
Dave M, Rankin J, Pearce M, Foster HE. Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J. 2020;18(1):49. https://doi.org/10.1186/s12969-020-00443-8 .
doi: 10.1186/s12969-020-00443-8
pubmed: 32532304
pmcid: 7291758
Migowa AN, Hadef D, Hamdi W, Mwizerwa O, Ngandeu M, Taha Y, et al. Pediatric rheumatology in Africa: thriving amidst challenges. Pediatr Rheumatol Online J. 2021;19(1):69. https://doi.org/10.1186/s12969-021-00557-7 .
doi: 10.1186/s12969-021-00557-7
pubmed: 33962643
pmcid: 8103667
Fatodu OO, Oyenuga OO. Effectiveness of health systems strengthening interventions in Africa: a systematic review. Int J Healthcare Policy. 2019;1(1):52–69. Available from: https://www.inderscienceonline.com/doi/abs/10.1504/IJHP.2019.101686 .
doi: 10.1504/IJHP.2019.101686
World Health Organization. World Report on Knowledge for Better Health: Strengthening Health Systems. World Health Organization; 2004. p.146. Available from: https://iris.who.int/handle/10665/43058 , https://www.who.int/rpc/wr2004 . Accessed 8 Dec 2023
Briggs AM, Schneider CH, Slater H, Jordan JE, et al. Heath systems strengthening to arrest the global disability burden: empirical development of prioritised components for a global strategy for improving musculoskeletal health. BMJ Glob Health. 2021;6(6):e006045. https://doi.org/10.1136/bmjgh-2021-006045 , https://gh.bmj.com/content/6/6/e006045 .
WHO. Expert Committee on the Selection and Use of Essential Medicines. The Selection and Use of Essential Medicines. World Health Organization; 2003. p. 127. Available from: https://iris.who.int/bitstream/handle/10665/42826/WHO_TRS_920.pdf . Accessed 8 Dec 2023.
Piggott T, Moja L, Akl EA, Lavis JN, Cooke G, Kredo T, et al. Decision criteria for selecting essential medicines and their connection to guidelines: an interpretive descriptive qualitative interview study. J Clin Epidemiol. 2023;154:146–55. https://doi.org/10.1016/j.jclinepi.2022.12.007 .
doi: 10.1016/j.jclinepi.2022.12.007
pubmed: 36584732
Persaud N, Jiang M, Shaikh R, Bali A, Oronsaye E, Woods H, et al. Comparison of essential medicines lists in 137 countries. Bull World Health Organ. 2019;97(6):394–404C. https://doi.org/10.2471/BLT.18.222448 .
doi: 10.2471/BLT.18.222448
pubmed: 31210677
pmcid: 6560372
Piggott T, Nowak A, Brignardello-Petersen R, Cooke GS, Huttner B, Schünemann HJ, et al. Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO. BMJ Open. 2022;12(2):e053349. https://doi.org/10.1136/bmjopen-2021-053349 .
doi: 10.1136/bmjopen-2021-053349
pubmed: 35144950
pmcid: 8845216
Foster HE, Scott C, Tiderius CJ, Dobbs MB, Members of the Paediatric Global Musculoskeletal Task Force. Improving musculoskeletal health for children and young people - A “call to action. Best Pract Res Clin Rheumatol. 2020;34(5):101566. https://doi.org/10.1016/j.berh.2020.101566 .
doi: 10.1016/j.berh.2020.101566
pubmed: 32727697
pmcid: 7382962
Foster HE, Scott C, Tiderius CJ, Dobbs MB. The paediatric global musculoskeletal task force - “towards better MSK health for all.” Pediatr Rheumatol Online J. 2020;18(1):60. https://doi.org/10.1186/s12969-020-00451-8 .
doi: 10.1186/s12969-020-00451-8
pubmed: 32664961
pmcid: 7359433
Tangcheewinsirikul S, Tang SP, Smith N, Sukharomana M, Charuvanij S, Vilaiyuk S, et al. Delivery of paediatric rheumatology care: a survey of current clinical practice in Southeast Asia and Asia-Pacific regions. Pediatr Rheumatol Online J. 2021;19(1):11. https://doi.org/10.1186/s12969-021-00498-1 .
doi: 10.1186/s12969-021-00498-1
pubmed: 33485337
pmcid: 7824936
Slamang W, Smith N, Scott C, Foster H, Paediatric Global MSK Task Force. Revising the WHO essential medicines list for paediatric rheumatology update. Pediatr Rheumatol Online J. 2022;20(1):89. https://doi.org/10.1186/s12969-022-00752-0 .
doi: 10.1186/s12969-022-00752-0
pubmed: 36241998
pmcid: 9569128
Foster HE, Scott C. Update the WHO EML to improve global paediatric rheumatology. Nat Rev Rheumatol. 2020;16(3):123. https://doi.org/10.1038/s41584-020-0368-6 .
doi: 10.1038/s41584-020-0368-6
pubmed: 31932748
Scott C, Smith N, James R, Whitehead B, Green R, Foster HE, et al. Revising the WHO essential medicines list for paediatric rheumatology. Pediatr Rheumatol Online J. 2021;19(1):10. https://doi.org/10.1186/s12969-021-00496-3 .
doi: 10.1186/s12969-021-00496-3
pubmed: 33485334
pmcid: 7824929
Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: Results from a five-year follow-up study. Arthritis Rheumatol. 2019;71(7):1163–73. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40865 .
doi: 10.1002/art.40865
pubmed: 30848528
pmcid: 6617757
Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Osterling Koskinen L, Kullenberg T, et al. Anakinra in children and adults with Still’s disease. Rheumatology. 2019;58(Suppl 6):vi9–22. https://doi.org/10.1093/rheumatology/kez350 .
doi: 10.1093/rheumatology/kez350
pubmed: 31769856
pmcid: 6878842
Malattia C, Ruperto N, Pederzoli S, Palmisani E, Pistorio A, Wouters C, et al. Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Res Ther. 2020;22(1):211. https://doi.org/10.1186/s13075-020-02303-y .
doi: 10.1186/s13075-020-02303-y
pubmed: 32912276
pmcid: 7488325
UNICEF. The State of the World’s Children 2023: For Every Child, Vaccination. UNICEF Innocenti - Global Office of Research and Foresight; 2023. Available from: https://www.unicef.org/reports/state-worlds-children-2023 . Accessed 9 Jan 2024.
Matlala M, Gous AGS, Meyer JC, Godman B. Formulary management activities and practice implications among public sector hospital pharmaceutical and therapeutics committees in a South African Province. Front Pharmacol. 2020;11:1267. https://doi.org/10.3389/fphar.2020.01267 .
doi: 10.3389/fphar.2020.01267
pubmed: 32973508
pmcid: 7466677
World Bank. Global Economic Prospects, June 2022. World Bank Publications; 2022. p. 194. Available from: https://thedocs.worldbank.org/en/doc/18ad707266f7740bced755498ae0307a-0350012022/original/Global-Economic-Prospects-June-2022 . Accessed Dec 2023.
Dey D, Paruk F, Mody GM, Kalla AA, Adebajo A, Akpabio A, et al. Women in rheumatology in Africa. The Lancet. 2022;4(10):e657–60. https://doi.org/10.1016/S2665-9913(22)00255-7 .
doi: 10.1016/S2665-9913(22)00255-7
pubmed: 38265961
Brown, De Benedetti. Disability and Health-Related Quality of Life Outcomes in Patients With Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated With Tocilizumab in …. Arthritis Rheum. Available from: https://cpg-medicaleducation.de/media/brunner_acr2019-1923_cherish_pros_1.pdf .
Tarkiainen M, Tynjälä P, Vähäsalo P, Kröger L, Aalto K, Lahdenne P. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):80. https://doi.org/10.1186/s12969-019-0370-1 .
doi: 10.1186/s12969-019-0370-1
pubmed: 31842940
pmcid: 6915981
Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: Therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74(4):553–69. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.42037 .
doi: 10.1002/art.42037
pubmed: 35233993
pmcid: 10161784
Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American college of rheumatology/arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res. 2019;71(6):717–34. https://doi.org/10.1002/acr.23870 .
doi: 10.1002/acr.23870
Adam T, de Savigny D. Systems thinking for strengthening health systems in LMICs: need for a paradigm shift. Health Policy Plan. 2012;27(Suppl 4):iv1–3. https://doi.org/10.1093/heapol/czs084 .
doi: 10.1093/heapol/czs084
pubmed: 23014149
Schneider CH, Parambath S, Young JJ, Jain S, Slater H, Sharma S, et al. From local action to global policy: a comparative policy content analysis of national policies to address musculoskeletal health to inform global policy development. Int J Health Policy Manag. 2023;12:7031. https://doi.org/10.34172/ijhpm.2022.7031 .
doi: 10.34172/ijhpm.2022.7031
pubmed: 37579444
pmcid: 10125103
Furia FF, Godfrey E, Mwamanenge N, Swai P. Spectrum of paediatric rheumatic disorders at a tertiary hospital in Tanzania. Pediatr Rheumatol Online J. 2020;18(1):30. https://doi.org/10.1186/s12969-020-0418-2 .
doi: 10.1186/s12969-020-0418-2
pubmed: 32245494
pmcid: 7126129
Migowa A, Bernatsky S, Ngugi AK, Foster HE, Muriuki P, Riang’a RM, et al. Bridging gaps: a qualitative inquiry on improving paediatric rheumatology care among healthcare workers in Kenya. Pediatr Rheumatol Online J. 2023;21(1):144. https://doi.org/10.1186/s12969-023-00935-3 .
doi: 10.1186/s12969-023-00935-3
pubmed: 38093255
pmcid: 10717234
Scott C, Sawhney S, Lewandowski LB. Pediatric rheumatic disease in lower to middle-income countries: impact of global disparities, ancestral diversity, and the path forward. Rheum Dis Clin North Am. 2022;48(1):199–215. https://doi.org/10.1016/j.rdc.2021.09.001 .
doi: 10.1016/j.rdc.2021.09.001
pubmed: 34798947
Australia Parliament. House of Representatives. Standing Committee on Health, Aged Care and Sport. Inquiry Into Childhood Rheumatic Diseases: Interim Report. Canberra; 2022. p. 55. Available from: https://nla.gov.au/nla.obj-3061217036/view . Accessed 8 Dec 2023.
Concha S, Morales PS, Talesnik E, Borzutzky A. Changes in treatments and outcomes after implementation of a national universal access program for juvenile idiopathic arthritis. J Rheumatol. 2021;48(11):1725–31. https://doi.org/10.3899/jrheum.210011 .
doi: 10.3899/jrheum.210011
pubmed: 33934075
Berard R, Batthish M. Addressing healthcare quality in juvenile idiopathic arthritis with a universal access program. J Rheumatol. 2021;48(11):1635–8. https://doi.org/10.3899/jrheum.210658 .
doi: 10.3899/jrheum.210658
pubmed: 34334363
Florax AA, Doeleman MJH, de Roock S, van der Linden N, Schatorjé E, Currie G, et al. Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing tumour necrosis factor-alfa inhibitors in juvenile idiopathic arthritis. Rheumatology. 2023 Dec 20. https://doi.org/10.1093/rheumatology/kead688
Eze P, Lawani LO, Agu UJ, Acharya Y. Catastrophic health expenditure in sub-Saharan Africa: systematic review and meta-analysis. Bull World Health Organ. 2022;100(5):337–51J. https://doi.org/10.2471/BLT.21.287673 .
doi: 10.2471/BLT.21.287673
pubmed: 35521041
pmcid: 9047424
Hanson H, Hart RI, Thompson B, McDonagh JE, Tattersall R, Jordan A, et al. Experiences of employment among young people with juvenile idiopathic arthritis: a qualitative study. Disabil Rehabil. 2018;40(16):1921–8. https://doi.org/10.1080/09638288.2017.1323018 .
doi: 10.1080/09638288.2017.1323018
pubmed: 28503954
Tukai M, George A, Delamare P, Toure CK, Tounkara A, Dembele A. Report on strengthening the warehouse management system for the pharmacie populaire du Mali. no April. 2016;1–35. Available from: https://siapsprogram.org/wp-content/uploads/2016/07/16-111-WMS-for-Mali-format.pdf .
Institute of Medicine, Board on Global Health, Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products. Countering the Problem of Falsified and Substandard Drugs. National Academies Press; 2013. 376 p. Available from: https://play.google.com/store/books/details?id=oBB1AgAAQBAJ .
Botwe BK. Model business process flows for registration of medicines: A guide for establishing a standardized generic version of SIAPS pharmadex software. Available from: https://siapsprogram.org/wp-content/uploads/2018/01/A-Guide-for-Establishing-a-Standardized-Generic-Version-of-SIAPS-Pharmadex-Software.pdf . Cited 2024 Jan 7.
Yenet A, Nibret G, Tegegne BA. Challenges to the availability and affordability of essential medicines in African countries: a scoping review. Clinicoecon Outcomes Res. 2023;15:443–58. https://doi.org/10.2147/CEOR.S413546 .
doi: 10.2147/CEOR.S413546
pubmed: 37332489
pmcid: 10276598
Anyanwu JC, Salami AO. The impact of COVID-19 on African economies: an introduction. Afr Dev Rev. 2021;33(Suppl 1):S1–16. https://doi.org/10.1111/1467-8268.12531 .
doi: 10.1111/1467-8268.12531
pubmed: 34149237
pmcid: 8207010
Sia SBBMB, Prisca K, Jotham K, Zhao C, Hermane G, Babuna P. The economic impact of COVID-19 on Africa and the countermeasures. Open J Bus Manag. 2023;11(02):416–36. Available from: https://www.scirp.org/journal/paperinformation.aspx?paperid=123050 .
Kim JY, Ammann A. Is the “3 by 5” initiative the best approach to tackling the HIV pandemic? PLoS Med. 2004;1(2):e37. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0010037 .
doi: 10.1371/journal.pmed.0010037
pubmed: 15578107
pmcid: 529425
Shayo EH, Murdoch J, Kiwale Z, Bachmann M, Bakari M, Mbata D, et al. Management of chronic conditions in resource limited settings: multi stakeholders’ perception and experiences with receiving and providing integrated HIV, diabetes and hypertension services in Tanzania. BMC Health Serv Res. 2023;23(1):1120. https://doi.org/10.1186/s12913-023-10123-4 .
doi: 10.1186/s12913-023-10123-4
pubmed: 37858150
pmcid: 10585858
Adeyemi O, Lyons M, Njim T, Okebe J, Birungi J, Nana K, et al. Integration of non-communicable disease and HIV/AIDS management: a review of healthcare policies and plans in East Africa. BMJ Glob Health. 2021;6(5). https://doi.org/10.1136/bmjgh-2020-004669
Kivuyo S, Birungi J, Okebe J, Wang D, Ramaiya K, Ainan S, et al. Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial. Lancet. 2023;402(10409):1241–50. https://doi.org/10.1016/S0140-6736(23)01573-8 .
doi: 10.1016/S0140-6736(23)01573-8
pubmed: 37805215
Murdoch J, Curran R, Cornick R, Picken S, Bachmann M, Bateman E, et al. Addressing the quality and scope of paediatric primary care in South Africa: evaluating contextual impacts of the introduction of the Practical Approach to Care Kit for children (PACK Child). BMC Health Serv Res. 2020;20(1):479. https://doi.org/10.1186/s12913-020-05201-w .
doi: 10.1186/s12913-020-05201-w
pubmed: 32471431
pmcid: 7257217
Campbell JA, Kessler EA, Shenoi S. Pediatric Telerheumatology. In: Peoples C, editor. Telerheumatology: Origins, Current Practice, and Future Directions. Cham: Springer International Publishing; 2022. p. 291–302. https://doi.org/10.1007/978-3-031-00936-5_20
Khubchandani R, Avčin T, Ravelli A. Towards telehealth delivery in pediatric rheumatology practice. Pediatr Rheumatol Online J. 2023;21(1):145. https://doi.org/10.1186/s12969-023-00892-x .
doi: 10.1186/s12969-023-00892-x
pubmed: 38105249
pmcid: 10726584